SEC Filing Summary: Alphabet Inc. Form 13F
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. for the reporting period ending June 30, 2022. The document discloses equity securities held by the company at the end of the quarter. It is a regulatory disclosure of investment holdings and does not contain Alphabet's own operational financial results (e.g., revenue, profit, or cash flow).
Key Financial Metrics
The filing text does not provide Alphabet Inc.'s revenue, profit, cash flow, margins, debt, or liquidity metrics. Instead, it lists the value and quantity of external equity securities held by Alphabet. Key portfolio statistics derived from the table include:
- Portfolio Composition: The holdings consist primarily of common stock and American Depositary Shares (ADS) in various technology, biotechnology, and healthcare companies.
- Top Holdings by Value:
- EQRX Inc: Total value approx. $221.9M (47.5M shares).
- Planet Labs PBC: Total value approx. $138.3M (31.9M shares).
- UiPath Inc: Total value approx. $248.5M (13.7M shares).
- Verve Therapeutics Inc: Total value approx. $164.9M (10.8M shares).
- 23andMe Holding Co: Total value approx. $16.7M (6.7M shares).
- Voting Authority: Alphabet reports "Sole" voting authority for the majority of listed positions.
Material Changes
The filing text does not provide comparative data against the prior quarter (March 31, 2022) or year-over-year changes. Consequently, material changes in the portfolio composition or value cannot be determined from this document alone.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, or specific risk factors related to Alphabet's operations. The document includes a standard SEC disclaimer stating that the Commission has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the total aggregate value of Alphabet's investment portfolio by summing the "Value" column, noting that this represents only a subset of holdings (those required to be reported).
- Confirm the specific CUSIP numbers for large positions (e.g., EQRX, UiPath, Verve) to ensure accurate tracking of share classes.
- Review Alphabet's official 10-Q or 10-K filings for the corresponding period to obtain actual revenue, profit, and cash flow data, as this Form 13F does not contain them.
- Check for subsequent filings (e.g., Q3 2022) to analyze changes in these specific biotech and tech holdings.